Tower Research Capital (TRC)’s Akoya BioSciences AKYA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-16,025
Closed -$20.8K 5202
2025
Q2
$20.8K Buy
16,025
+7,658
+92% +$9.21K ﹤0.01% 3657
2025
Q1
$11.6K Buy
8,367
+4,151
+98% +$9.09K ﹤0.01% 3523
2024
Q4
$9.65K Buy
4,216
+2,518
+148% +$6.67K ﹤0.01% 3889
2024
Q3
$4.62K Sell
1,698
-5,029
-75% -$12.3K ﹤0.01% 4474
2024
Q2
$15.7K Buy
6,727
+5,414
+412% +$17.3K ﹤0.01% 3896
2024
Q1
$6.16K Sell
1,313
-9,095
-87% -$47.2K ﹤0.01% 4423
2023
Q4
$50.8K Buy
10,408
+7,746
+291% +$32.2K ﹤0.01% 3126
2023
Q3
$12.4K Buy
2,662
+2,108
+381% +$12.1K ﹤0.01% 3895
2023
Q2
$4.09K Sell
554
-689
-55% -$4.6K ﹤0.01% 4988
2023
Q1
$10K Sell
1,243
-377
-23% -$3.94K ﹤0.01% 4319
2022
Q4
$16K Buy
1,620
+121
+8% +$1.49K ﹤0.01% 3316
2022
Q3
$18K Buy
1,499
+306
+26% +$4.03K ﹤0.01% 3998
2022
Q2
$15K Sell
1,193
-411
-26% -$4.26K ﹤0.01% 4050
2022
Q1
$17K Buy
1,604
+498
+45% +$5.78K ﹤0.01% 3672
2021
Q4
$17K Buy
1,106
+213
+24% +$2.79K ﹤0.01% 3827
2021
Q3
$12K Sell
893
-1,905
-68% -$31.9K ﹤0.01% 4131
2021
Q2
$54K Buy
+2,798
New +$57.8K ﹤0.01% 2961

Tower Research Capital (TRC)'s AKYA Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 16,025 shares — an estimated $20.8K sold.

Tower Research Capital (TRC) first reported a position in AKYA in Q2 2021 and held it in 17 quarters. The position peaked at $54K in Q2 2021. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 16,025 Akoya BioSciences shares in Q3 2025, an estimated $20.8K.
  • Tower Research Capital (TRC) first reported a position in Akoya BioSciences in Q2 2021 and held it in 17 quarters.
  • Tower Research Capital (TRC)'s Akoya BioSciences position peaked at $54K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.